At present, the clinical prevention and treatment modalities include using HMG-CoA reductase inhibitor statins to reduce plasma LDL-C, but the incidence of serious cardiovascular and cerebrovascular diseases related to atherosclerosis is still on the rise in the context of widely used statins to achieve the expected lipid regulation level [36]. This evidence concerns the gene HMGCR and cerebrovascular disorder.